Skip to content
What if… The small intestine functions as a control center for the entire immune system?
It turns out…

We can identify specific strains of microbes that target and engage with immune cells in the small intestine to direct systemic immune responses for the treatment of inflammatory diseases and beyond.

Founded by Flagship Pioneering in 2015, Evelo Biosciences (NASDAQ: EVLO) is a clinical-stage biotechnology company developing a novel platform of orally delivered medicines harnessing the central biology of the small intestinal axis, SINTAX. Evelo’s product candidates are pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles (EVs) developed to engage cells in the small intestine with systemic therapeutic effects. Evelo’s therapies have the potential to be effective, safe, well-tolerated, convenient, and affordable medicines to improve the lives of hundreds of millions of people at all stages of inflammatory disease.

Latest News from Evelo Biosciences